吉非替尼靶向介导在 sIMRT 治疗非小细胞肺癌中的应用分析

摘要

Objective To investigate application of gefitinib mediated targeting for sIMRT in the treatment of non-small cell lung cancer. Methods 112 patients with non-small cell lung cancer March 2012 to September 2013 were divided into two groups according to the order of admission. All patients were treated with sIMRT technology, and the observation group (n = 62) was given 250mg/ d of gefitinib. The efficiency and the incidence of adverse reac-tions were observed after treatment. Results The effective rate was 96. 77% in the observation group and 72. 00%in the control group (u = 2. 0737, P = 0. 0381). The incidence of diarrhea, nausea, vomiting, abnormal liver func-tion, and lung function abnormalities was clearly lower in the observation group than in the control group ( P <0. 05). Conclusion Gefitinib mediated targeting for sIMRT can improve their efficacy and reduce toxic side effect in the treatment of non-small cell lung cancer.%目的：研究吉非替尼靶向介导在简化调强放疗技术(sIMRT)治疗非小细胞肺癌中的应用。方法选择2012年3月至2013年9月我院收治的112例非小细胞肺癌患者,按照患者入院的顺序,分为观察组(62例)和对照组(50例)。所有患者均采用简化调强放疗技术(sIMRT)技术,观察组患者在此基础上,均服用250 mg/ d 的吉非替尼。观察两组患者治疗后的有效率和不良反应发生率,并对其进行比较分析。结果观察组患者治疗的有效率(96．77%)明显高于对照组(72．00%),两组比较有统计学意义(u =2．0737,P =0．0381)。观察组患者在皮肤,腹泻,恶心、呕吐,肝功能异常,肺功能异常不良反应率方面显然低于对照组,两组比较差异具有统计学意义(P <0．05)。结论吉非替尼靶向介导在简化调强放疗技术(sIMRT)治疗非小细胞肺癌中,具有改善疗效,提高患者生存率的作用,并且毒性副作用小,具有较好的耐受性,值得在临床上广泛推广使用。